Drug
Sgn 15
Sgn 15: highest development phase Phase 2, developed by Seagen. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| SGN-15 NCT00051571 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| SGN-15 (cBR96-doxorubicin immunoconjugate) NCT00031187 | Phase 2 | Prostatic Neoplasms |
Latest
No recent events.
Follow Sgn 15 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.